Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity.

[1]  J. Rees.  Androgen deprivation therapy and cardiovascular risk. , 2015, The Practitioner.

[2]  F. Montorsi,et al.  Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: A population‐based analysis , 2012, International journal of urology : official journal of the Japanese Urological Association.

[3]  M. Wirth,et al.  Which patients are at the highest risk of dying from competing causes ≤10 years after radical prostatectomy? , 2012, BJU international.

[4]  M. Cooperberg,et al.  Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram , 2012, Prostate Cancer and Prostatic Diseases.

[5]  M. Kattan,et al.  Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. , 2012, The Journal of urology.

[6]  Jim C Hu,et al.  Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. , 2011, JAMA.

[7]  S. Alibhai.  Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates , 2011, Cancer.

[8]  P. Ghadjar,et al.  Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. , 2011, Cancer.

[9]  Rosalia Viterbo,et al.  Long‐term survival after radical prostatectomy versus external‐beam radiotherapy for patients with high‐risk prostate cancer , 2011, Cancer.

[10]  C. Simone.  Re: Firas Abdollah, Maxine Sun, Rodolphe Thuret, et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol 2011;59:88-95. , 2011, European urology.

[11]  Dirk F Moore,et al.  Impact of comorbidity on survival among men with localized prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Greenfield,et al.  Overtreatment of men with low‐risk prostate cancer and significant comorbidity , 2011, Cancer.

[13]  L. Holmberg,et al.  Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. , 2011, The Journal of urology.

[14]  Jack Hadley,et al.  Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. , 2010, Journal of the National Cancer Institute.

[15]  M. Cooperberg,et al.  Comparative risk‐adjusted mortality outcomes after primary surgery, radiotherapy, or androgen‐deprivation therapy for localized prostate cancer , 2010, Cancer.

[16]  A. Partin,et al.  Prediction of mortality after radical prostatectomy by Charlson comorbidity index. , 2010, Urology.

[17]  B. Psaty,et al.  Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction. , 2010, JAMA.

[18]  Christian Hyde.  Rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer (Int J Radiat Oncol Biol Phys 2010;76:342-348). , 2010, International journal of radiation oncology, biology, physics.

[19]  Pär Stattin,et al.  Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study , 2010, Journal of the National Cancer Institute.

[20]  Umberto Capitanio,et al.  The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. , 2010, International journal of radiation oncology, biology, physics.

[21]  Christopher S Coffey,et al.  Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. D'Amico,et al.  Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. , 2009, JAMA.

[23]  Mark S Litwin,et al.  Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. , 2009, Journal of the National Cancer Institute.

[24]  F. Saad,et al.  Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study. , 2009, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[25]  Wadih Arap,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[26]  Xianglin L. Du,et al.  Long‐term survival after radical prostatectomy compared to other treatments in older men with local/regional prostate cancer , 2008, Journal of surgical oncology.

[27]  P. Carroll,et al.  Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. , 2008, The Journal of urology.

[28]  A. Renshaw,et al.  Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. , 2008, JAMA.

[29]  J. Coebergh,et al.  Impact of comorbidity on treatment and prognosis of prostate cancer patients: a population-based study. , 2006, Critical reviews in oncology/hematology.

[30]  I. C. Tudor,et al.  The risk associated with aprotinin in cardiac surgery. , 2006, The New England journal of medicine.

[31]  Edward L Spitznagel,et al.  Prognostic importance of comorbidity in a hospital-based cancer registry. , 2004, JAMA.

[32]  F. Gilliland,et al.  Effects of misattribution in assigning cause of death on prostate cancer mortality rates. , 2003, Annals of epidemiology.

[33]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[34]  F. Montorsi,et al.  A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. , 2011, European urology.

[35]  C. Lawton.  Duration of Androgen Suppression in the Treatment of Prostate Cancer , 2010 .

[36]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.